Clinical Trial Update: Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial investigating intravenous autologous mesenchymal stem cells for multiple sclerosis showed safety and efficacy signals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Autologous mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED